세계의 표준 펜니들 시장 예측(-2032년) : 약제 유형, 적응 질환, 니들 사이즈, 사용성, 구매 형태, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Standard Pen Needles Market is accounted for $1.69 billion in 2025 and is expected to reach $3.06 billion by 2032 growing at a CAGR of 8.8% during the forecast period. Standard pen needles are thin, single-use medical needles that connect to insulin pens or similar injection devices. They enable accurate and controlled delivery of medications under the skin. Available in various lengths and thicknesses, these needles are designed to enhance patient comfort and dosing precision. Their disposable nature helps prevent infection and contamination, making them a safe and convenient option for self-administering injectable treatments.

According to the International Diabetes Federation (IDF), over 530 million adults were living with diabetes in 2023, and this number is expected to rise in the coming decades.

Market Dynamics:

Driver:

Increasing patient preference for insulin pens

The growing prevalence of chronic illnesses like diabetes is fueling demand for convenient drug delivery systems. Insulin pens are gaining popularity due to their ease of use, portability, and reduced injection pain compared to traditional syringes. Technological advancements in pen needle design are improving patient comfort and dosage accuracy. As healthcare shifts toward personalized treatment, insulin pens are becoming integral to daily disease management. The rise in elderly populations and improved diagnostic rates are further boosting adoption. Emerging markets are witnessing increased uptake due to expanding access to diabetes care and education.

Restraint:

Shift towards safety pen needles

The transition toward safety pen needles is introducing regulatory and cost-related hurdles for manufacturers. These devices require compliance with stringent safety standards, including mechanisms to prevent needlestick injuries. Incorporating safety features often increases production complexity and cost, impacting profit margins. Smaller players face challenges in meeting global certification requirements like ISO and FDA approvals. The integration of smart technologies such as needle tracking and disposal sensors adds further regulatory scrutiny. These factors can slow down innovation and delay product launches in competitive markets.

Opportunity:

Rising trend of self-administration

The growing trend of self-administered therapies is creating new opportunities for standard pen needles. Patients are increasingly managing chronic conditions at home, driving demand for user-friendly and reliable injection devices. Innovations in needle ergonomics and ultra-thin designs are enhancing comfort and reducing anxiety. Disposable pen needles are gaining traction due to hygiene concerns and infection control protocols. Manufacturers are exploring biodegradable materials and smart packaging to align with sustainability goals. This shift is also supported by telehealth platforms and remote monitoring technologies that empower patient autonomy.

Threat:

Stringent regulations on safety devices

Regulatory frameworks governing safety devices are becoming more complex and demanding. Authorities require extensive clinical validation and documentation before approving new needle technologies. The rise of digital features like dose tracking and connectivity adds layers of compliance challenges. Supply chain disruptions and material shortages can further complicate regulatory timelines. Companies without robust regulatory teams may struggle to navigate evolving standards, especially in cross-border markets. These constraints can hinder innovation and limit the speed of market expansion.

Covid-19 Impact:

Lockdowns and healthcare reprioritization delayed routine diabetes care and elective treatments. However, the crisis accelerated the adoption of home-based care and self-injection practices. Regulatory bodies introduced fast-track approvals for essential medical devices, including pen needles. Digital health platforms and remote consultations supported continuity of care during the pandemic. Post-COVID strategies now emphasize supply chain resilience, automation, and decentralized production to ensure uninterrupted access.

The insulin segment is expected to be the largest during the forecast period

The insulin segment is expected to account for the largest market share during the forecast period, driven by the rising global burden of diabetes and the widespread use of insulin therapy. Technological improvements in insulin delivery systems are enhancing precision and patient adherence. Pen needles designed for insulin pens are becoming more sophisticated, with features like shorter lengths and finer gauges. Healthcare providers are increasingly recommending insulin pens for better glycemic control and reduced injection errors. As insulin therapy becomes more personalized, demand for compatible pen needles continues to surge.

The home healthcare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate. Rising healthcare costs and patient preference for at-home treatment are driving this shift. Pen needles are essential tools for self-injection, making them central to home-based chronic disease management. Innovations in packaging and needle safety are making these devices more accessible for non-clinical users. Telemedicine and remote monitoring technologies are reinforcing the trend toward decentralized care. As healthcare systems evolve, home healthcare is emerging as a key growth engine for pen needle manufacturers.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share. Rapid urbanization and increasing diabetes prevalence are fuelling demand across countries like China, India, and Japan. Government initiatives promoting local manufacturing and affordable healthcare are boosting market penetration. The region is witnessing strong adoption of digital health tools and smart injection devices. Strategic collaborations between global brands and regional players are accelerating technology transfer. Investments in healthcare infrastructure and public awareness campaigns are further expanding the user base.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. The region leads in technological innovation, with advanced needle designs and integrated safety features. Regulatory agencies are streamlining approval processes for next-gen injection devices, encouraging rapid commercialization. High adoption of self-care and remote health management is driving demand for user-friendly pen needles. Healthcare providers are leveraging data analytics and IoT to optimize chronic disease treatment protocols. Robust reimbursement frameworks and strong R&D investments are reinforcing North America's leadership in this space.

Key players in the market

Some of the key players in Standard Pen Needles Market include Becton, Dickinson and Company, Berpu Medical Technology Co., Ltd., Novo Nordisk A/S, HTL-STREFA, Embecta Corp., GlucoRx Limited, Ypsomed AG, ARKRAY, Inc., B. Braun SE, AdvaCarePharma, Owen Mumford Ltd., Allison Medical, Inc., Terumo Corporation, UltiMed, Inc., and NIPRO Corporation.

Key Developments:

In September2025, BD (Becton, Dickinson and Company) announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a robotic solution that will enable patients to pick up select prescriptions at their convenience 24 hours a day, seven days a week.

In May2025, Novo Nordisk and Septerna, Inc. announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.

DrugTypes Covered:

• Insulin
• Growth Hormone
• GLP-1
• Other Drug Types

Disease Indications Covered:

• Diabetes
• Hormone Deficiency
• Obesity

Needle Sizes Covered:

• 4 mm
• 5 mm
• 6 mm
• 8 mm
• 12 mm

UsabilitiesCovered:

• Disposable Pen Needles
• Reusable Pen Needles

Mode of Purchases Covered:

• Retail
• Online Purchase
• Non-Retail Channels

End Users Covered:

• Hospitals
• Home Healthcare
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Standard Pen Needles Market, By Drug Type

• 5.1 Introduction
• 5.2 Insulin
• 5.3 Growth Hormone
• 5.4 GLP-1
• 5.5 Other Drug Types

6 Global Standard Pen Needles Market, By Disease Indication

• 6.1 Introduction
• 6.2 Diabetes
• 6.3 Hormone Deficiency
• 6.4 Obesity

7 Global Standard Pen Needles Market, By Needle Size

• 7.1 Introduction
• 7.2 4 mm
• 7.3 5 mm
• 7.4 6 mm
• 7.5 8 mm
• 7.6 12 mm

8 Global Standard Pen Needles Market, By Usability

• 8.1 Introduction
• 8.2 Disposable Pen Needles
• 8.3 Reusable Pen Needles

9 Global Standard Pen Needles Market, By Mode of Purchase

• 9.1 Introduction
• 9.2 Retail
• 9.3 Online Purchase
• 9.4 Non-Retail Channels

10 Global Standard Pen Needles Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Home Healthcare
• 10.4 Clinics
• 10.5 Other End Users

11 Global Standard Pen Needles Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Becton, Dickinson and Company
• 13.2 Berpu Medical Technology Co., Ltd.
• 13.3 Novo Nordisk A/S
• 13.4 HTL-STREFA
• 13.5 Embecta Corp.
• 13.6 GlucoRx Limited
• 13.7 Ypsomed AG
• 13.8 ARKRAY, Inc.
• 13.9 B. Braun SE
• 13.10 AdvaCare Pharma
• 13.11 Owen Mumford Ltd.
• 13.12 Allison Medical, Inc.
• 13.13 Terumo Corporation
• 13.14 UltiMed, Inc.
• 13.15 NIPRO Corporation